

Company Overview

NxStage Medical, Inc. (Nasdaq: [NXTM](#)) is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products and services for the treatment of end-stage renal disease (ESRD) and acute kidney failure for use in a variety of settings, including patient homes, as well as more traditional care settings such as hospitals and dialysis centers.

The NxStage System One was designed to satisfy an unmet clinical need for a system that can deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller, portable, easy-to-use form that can be used by healthcare professionals and trained lay users alike in a variety of settings, including patients homes, as well as more traditional settings such as hospitals and dialysis centers. Given its design, the System One is particularly well suited for home hemodialysis and a range of dialysis therapies that are more practical to deliver in the home setting, including more frequent home hemodialysis and nocturnal dialysis, which clinical literature suggests provides patients with better clinical outcomes and improved quality of life.

Home Dialysis:

The NxStage[®] System One[™] is the first and only truly portable hemodialysis system cleared by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow[™] SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. In addition, Nx2me Connected Health[®] platform collects important NxStage System One and patient information for flexible viewing, monitoring and reporting that may improve patient management and simplify alternative site care.

Critical Care:

In addition to the home market, the NxStage System One with NxView was also designed to simplify the delivery of renal replacement therapy in acute care settings. The device offers multiple therapy options including therapeutic plasma exchange, hemofiltration, isolated ultrafiltration, SHIFT, and hemodialysis. The portability and simplicity of set-up enables critical care staff to bring the therapy to the patient, increasing flexibility and efficiency to renal care staff.

NxStage Kidney Care:

NxStage also has established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD.

For a listing of NxStage Kidney Care centers please visit the website at www.nxstagekidneycare.com.

The Company also manufactures and distributes a variety of innovative disposables, providing safe, convenient, efficient and cost effective use in hemodialysis, apheresis and other extracorporeal therapies under the Medisystems brand.

Company History

Headquartered in Lawrence, Mass., NxStage was founded in 1998 by Jeffrey Burbank, Chief Executive Officer. Under Burbank's leadership, NxStage has steadily advanced as a leader in renal care. The Company's primary product, the System One was first launched in the critical care market in 2003 and then later received FDA clearance for home hemodialysis in June 2005. Also in 2005, NxStage went public on the Nasdaq stock exchange and began trading under the ticker symbol, "NXTM". In 2014 the NxStage System One received clearance from the FDA for home nocturnal hemodialysis. The System One remains the first and only portable hemodialysis system cleared by the FDA for home hemodialysis and home nocturnal hemodialysis.

Currently 8 of the top 10 leading renal care hospitals as ranked by *U.S. News & World Report* use the System One in acute care settings and we market our extracorporeal disposable products under the Medisystems brand, which we acquired in 2007. Medisystems branded products have an established reputation for quality, ease of use and innovation, and have been in the in-center market since 1981.

NxStage sells the System One in 23 countries around the world, including Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, New Zealand, and Sweden; NxStage has also moved to direct sales in both Canada and the United Kingdom.

For more information on NxStage and its products and services, please visit the Company's websites at www.nxstage.com and www.nxstagekidneycare.com.